<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04264377</url>
  </required_header>
  <id_info>
    <org_study_id>201900308</org_study_id>
    <nct_id>NCT04264377</nct_id>
  </id_info>
  <brief_title>Towards Targeting the ORigin of the Inflammatory Cascade in Allergic Asthma</brief_title>
  <acronym>ORIENT</acronym>
  <official_title>Towards Targeting the ORigin of the Inflammatory Cascade in Allergic Asthma: Cross-talk Between Airway Epithelium and Immune Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allergic asthma is a complex and heterogeneous disease caused by excessive responses to&#xD;
      inhaled allergens. Current medication, including corticosteroids and bronchodilators, does&#xD;
      not act on the origin of inflammation but rather combats symptoms, leaving many patients&#xD;
      uncontrolled. Airway epithelium is critical for the initiation and progression of asthma&#xD;
      pathology.&#xD;
&#xD;
      We will include a 52 subjects divided over two groups: ongoing asthma (26 patients) and&#xD;
      non-asthmatic healthy controls (26 subjects) in a cross-sectional study. All subjects will be&#xD;
      extensively clinically characterized including respiratory symptoms/questionnaires, in- and&#xD;
      expiratory CT-scans, and parameters of large and small airway function and inflammation. In&#xD;
      addition, blood and nasal epithelial brushes will be obtained to study the genetic and&#xD;
      epigenetic mechanisms of asthma. Finally, bronchoscopy with bronchial biopsies and brushes&#xD;
      will be performed under conscious sedation. Bronchial biopsies from both patient groups will&#xD;
      be used for single cell transcriptional analysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Single-cell transcriptomics bronchial epithelial cell (BEC)</measure>
    <time_frame>december 2022</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Asthma</condition>
  <condition>Allergic Asthma</condition>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <description>26 healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asthma</arm_group_label>
    <description>26 subjects with asthma</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bronchoscopy</intervention_name>
    <description>Bronchoscopy for retrieval of airway cells</description>
    <arm_group_label>Asthma</arm_group_label>
    <arm_group_label>Healthy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Asthma and healthy subjects&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion criteria for all subjects:&#xD;
&#xD;
          -  Age between 18 and 45 years old.&#xD;
&#xD;
          -  Smoking history ≤2 packyears.&#xD;
&#xD;
        Specific inclusion criteria for the two groups:&#xD;
&#xD;
          -  Group 1. Patients with ongoing asthma&#xD;
&#xD;
               -  Age of onset of asthmatic symptoms: 0 - 18 years.&#xD;
&#xD;
               -  Documented history of asthma diagnosed according to latest GINA guidelines, i.e.&#xD;
                  respiratory symptoms and either bronchodilator reversibility (improvement in FEV1&#xD;
                  of more than 12% of baseline (and at least 200 mL) after inhalation of 800 µg&#xD;
                  salbutamol).&#xD;
&#xD;
               -  Use of inhaled corticosteroids or either persistent symptoms of wheeze, cough, or&#xD;
                  dyspnea or regular use of β2 agonists at least once a week during the last 2&#xD;
                  months.&#xD;
&#xD;
               -  PC20 methacholine &lt; 8 mg/ml.&#xD;
&#xD;
          -  Group 2. Non-asthmatic controls&#xD;
&#xD;
               -  No history of asthma.&#xD;
&#xD;
               -  No use of inhaled corticosteroids or β2-agonists for a period longer than 1&#xD;
                  month.&#xD;
&#xD;
               -  No symptoms of wheeze, nocturnal dyspnea, or bronchial hyperresponsiveness.&#xD;
&#xD;
               -  PC20 methacholine &gt; 8 mg/ml, FEV1/FVC &gt; 70% and FEV1 &gt; 80% predicted.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  FEV1 &lt;1.2 L,&#xD;
&#xD;
          -  Subjects must be able to adhere to the study visit schedule and other protocol&#xD;
             requirements.&#xD;
&#xD;
          -  A subject is not eligible to enter and participate if he has not signed and dated a&#xD;
             written informed consent form prior to participation in the study.&#xD;
&#xD;
          -  A subjects is not eligible to enter and participate if he does not agree that we&#xD;
             inform his general practitioner.&#xD;
&#xD;
          -  Upper respiratory tract infection (e.g. colds), within 6 weeks.&#xD;
&#xD;
          -  Serious acute infections (such as hepatitis, pneumonia or pyelonephritis) in the&#xD;
             previous 3 months.&#xD;
&#xD;
          -  Signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic,&#xD;
             endocrine, pulmonary, cardiac, neurologic or cerebral disease.&#xD;
&#xD;
          -  Malignancy within the past 5 years (except for squamous or basal cell carcinoma of the&#xD;
             skin that has been treated with no evidence of recurrence).&#xD;
&#xD;
          -  Known recent substance abuse (drug or alcohol).&#xD;
&#xD;
          -  Females of childbearing potential without an efficient contraception unless they meet&#xD;
             the following definition of post-menopausal: 12 months of natural (spontaneous)&#xD;
             amenorrhea or 6 months of spontaneous amenorrhea with serum FSH &gt;40 mIU/mL or the use&#xD;
             of one or more of the following acceptable methods of contraception:&#xD;
&#xD;
               1. Surgical sterilization (e.g. bilateral tubal ligation, hysterectomy).&#xD;
&#xD;
               2. Hormonal contraception (implantable, patch, oral, injectable).&#xD;
&#xD;
               3. Barrier methods of contraception: condom or occlusive cap (diaphragm or&#xD;
                  cervical/vault caps) with spermicidal foam/gel/cream/suppository.&#xD;
&#xD;
               4. Continuous abstinence.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maarten van den Berge, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMCG</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maarten van den Berge, Dr</last_name>
    <phone>+3150-3615260</phone>
    <email>m.van.den.berge@umcg.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maarten van den Berge, MD, PhD</last_name>
      <phone>+31-50-2615260</phone>
      <email>m.van.den.berge@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>Maarten van den Berge, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 7, 2020</study_first_submitted>
  <study_first_submitted_qc>February 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2020</study_first_posted>
  <last_update_submitted>February 7, 2020</last_update_submitted>
  <last_update_submitted_qc>February 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Maarten van den Berge</investigator_full_name>
    <investigator_title>Dr. M. van den Berge</investigator_title>
  </responsible_party>
  <keyword>Epigenetics</keyword>
  <keyword>Airway wall remodeling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

